The Increasing Investment on Research is propelling the Growth of the Doxorubicin Market in the APAC Region!

The Asia Pacific doxorubicin market is a significant and growing segment of the global doxorubicin market. The Asia Pacific region includes countries such as China, India, Japan, and Australia, among others. The improving healthcare infrastructure, along with the increasing investments in research & development of cancer drugs is the major contributing factor to the market growth of doxorubicin in the APAC region. For instance, Shanghai Pudong Hospital is conducting clinical trials to evaluate the cardiac safety of pegylated liposomal doxorubicin concurrently plus trastuzumab and pertuzumab in the adjuvant setting for early-stage HER-2-positive breast cancer in China.

Access sample report (including graphs, charts, and figures): https://univdatos.com/get-a-free-sample-form-php/?product_id=43819

Further, the Asia-Pacific Doxorubicin Market is expected to grow at a strong CAGR of 6% during the forecast period (2022-2030). The increasing risk of cancer in the population is due to the changing lifestyle and increasing pollution in the region.

FIG. 1 APAC Doxorubicin Market Revenue (2020-2030)- USD Mn

Based on drug formulation, the market is segmented into lyophilized powder and doxorubicin injection. As per our analysis, the doxorubicin injection segment is expected to grow at a considerable rate during the forecast period. Doxorubicin Injection is administered intravenously (IV) and is used to treat various types of cancer, including breast cancer, ovarian cancer, lung cancer, and others. The injections absorb easily inside the body, and these injections are easily available which is an important factor responsible for the growth of the segment in the doxorubicin market.

Based on the application, the market is segmented into bladder cancer, kaposi sarcoma, leukemia, lymphoma, breast cancer, and others. The leukemia segment is expected to grow with a higher CAGR in the doxorubicin market during the forecast period. The prevalence of leukemia is high and the cases of the disease are growing at a rapid pace is an important factor responsible for the growth of the segment. For instance, as per the Globocan, 4500 new cases of leukemia were reported in Australia in 2020.

Based on the distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. As per our analysis, the online pharmacy segment is expected to grow at a considerable rate during the forecast period. Online pharmacies are becoming increasingly popular in the doxorubicin market, as they provide a convenient and cost-effective option for patients to purchase their medications. Further, the adoption of mobile phones is increasing, which is also an important factor for the rapid growth of the segment.

For a detailed analysis of Global Doxorubicin Market browse through – https://univdatos.com/report/doxorubicin-market/

Global Doxorubicin Market Segmentation

Market Insight, by Drug Formulation

• Lyophilized Powder
• Doxorubicin Injection

Market Insight, by Application

• Bladder Cancer
• Kaposi Sarcoma
• Leukemia
• Lymphoma
• Breast Cancer
• Others

Market Insight, by Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Market Insight, by Region

• North America
  • U.S.
  • Canada
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• APAC
  • China
  • Japan
  • India
  • Rest of APAC
• Rest of the World

Top Company Profiles

• Intas Pharmaceuticals Ltd.
• Cipla Inc.• Dr. Reddy’s Laboratories Ltd.• Cadila Pharmaceuticals• Meiji Holdings Co., Ltd.• Johnson & Johnson Private Limited.• Novartis AG• Pfizer Inc.• Sun Pharmaceutical Industries Ltd.• Baxter